CureVac & Sanofi Pasteur Ink Pacts to Develop Vaccines against Infectious Diseases

Under the terms of the license agreements, CureVac may receive an upfront payment from Sanofi Pasteur for each pathogen, research funding and payments for achieving several clinical, regulatory and commercial milestones.

CureVac GmbH has announced the signing of several agreements with Sanofi Pasteur S.A. to further develop and apply CureVac’s proprietary RNActive? technology platform to the development of vaccines against several infectious diseases.

A research proposal with total funding of $33.1 million involving a collaboration among CureVac, Sanofi Pasteur (including Sanofi Pasteur VaxDesign Corp.) and In-Cell-Art S.A.S., a French biotech company contributing its nanoparticle technology, has been selected by DARPA, the Defense Advanced Research Projects Agency (an agency of the United States Department of Defense). In this 4-year project, CureVac and the other parties to the collaboration will further advance key aspects of CureVac’s RNActive? technology platform and will evaluate several vaccine candidates in a number of relevant disease models.